cryptocurrency no value Top

The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Market news: South Korea's ruling party has elected a new party leader, and the new leader said that a presidential election may be held soon.Tsinghua University National Key Laboratory Base was established in Changping National Heavy Base at the end of the first phase. At present, Changping District is cooperating with Tsinghua University to build Tsinghua Nankou National Heavy Base, revitalizing the industrial remains of the "three major factories" in Nankou Town through urban renewal, and undertaking more than 14 national key laboratories in Tsinghua University. It is expected to be put into use in 2025, which will be the largest and most concentrated national key laboratory research base outside the main campus of Tsinghua University. Among them, two laboratories, Intelligent Green Vehicle and Transportation and New Power Operation and Control, will be completed and unveiled at the end of December this year. (Beijing Daily)

Binhua Co., Ltd. set up a new equipment technology company in Shandong. According to the enterprise search APP, Shandong Hualu Dingcheng Equipment Technology Co., Ltd. was established recently. The legal representative is Dong Hongbo, with a registered capital of 10 million yuan. Its business scope includes: cloud computing equipment technical services; Intelligent basic manufacturing equipment manufacturing; Intelligent basic manufacturing equipment sales. Enterprise equity penetration shows that the company is wholly owned by Binhua shares.The Chinese medicine sector collectively pulled up Panlong Pharmaceutical's linear daily limit, Panlong Pharmaceutical's linear daily limit, Xiangxue Pharmaceutical, Kunyao Group, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical and Changyao Holdings followed suit.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.

CICC and others set up a venture capital partnership in Xiamen. According to the enterprise search APP, Zhongjin Qiyuan Phase II (Xiamen) Venture Capital Partnership (Limited Partnership) was recently established with a capital contribution of 400 million yuan. Its business scope includes: engaging in equity investment, investment management, asset management and other activities with private equity funds. Enterprise investigation shows that the company is jointly held by CICC Capital Operation Co., Ltd., a wholly-owned subsidiary of CICC.OPEC continues to lower its global oil demand forecast. According to Xinhua News Agency, the Organization of Petroleum Exporting Countries (OPEC) released its monthly oil market report on the 11th, lowering its global oil demand forecast for 2024 and 2025. This is the fifth time that OPEC has lowered its global oil demand forecast for this year and next since August this year.Zou Yingguang, General Manager of CITIC Securities: It is expected that the demand for cross-border investment and financing at home and abroad will be further released. At the investor open day of CITIC Securities in 2024, Zou Yingguang, General Manager of CITIC Securities, said that the demand for two-way cross-border investment and financing is very strong, whether it is a China enterprise "going abroad" or an overseas investor "coming to China". Among them, with the rapid evolution of China's new open economic system, cross-border finance will usher in greater development space, and securities companies will be in cross-border finance. In the medium and long term, China's macro securitization rate is still accelerating, the internationalization of Chinese-funded enterprises will continue to increase, and the opening up of China's capital market will continue to increase. It is expected that the demand for cross-border investment and financing from domestic and foreign customers will be further released.